Pfizer reached an amended agreement to acquire obesity drug developer Metsera for about $10 billion after a week-long auction that saw Novo Nordisk withdraw its competing offer. The deal gives Pfizer ownership of Metsera’s portfolio, including GLP-1 and amylin assets and several oral candidates. Company statements and reporting indicate the transaction clears near-term regulatory and shareholder milestones and positions Pfizer to enter the high-growth obesity market immediately. The takeover follows aggressive valuation moves and explicit political interest that shaped the final terms. Coverage noted that U.S. regulators granted early clearance to the transaction and Metsera expects to close shortly after its stockholder meeting. Observers highlighted the strategic rationale: Pfizer fills a pipeline gap in metabolic drugs while assuming integration and commercial risk for late-stage assets. Buyout mechanics and stakeholder reactions were widely reported; investment groups and venture backers are expected to realize substantial proceeds. The deal underscores continued M&A appetite for obesity and metabolic franchises and will reshape competitive dynamics between Big Pharma incumbents and specialized biotech developers.